Download PDF
Hamostaseologie 2017; 37(04): 277-285
DOI: 10.5482/HAMO-16-07-0029
Review
Schattauer GmbH

Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation

Fortschritte im antikoagulativen Management von Patienten bei Kardioversion eines nichtvalvulären Vorhofflimmerns
Georgios Benetos
1   Department of Cardiology, Laikon General Hospital, Athens, Greece
,
Maria Bonou
1   Department of Cardiology, Laikon General Hospital, Athens, Greece
,
Konstantinos Toutouzas
2   First Department of Cardiology, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece
,
Panagiotis Diamantopoulos
3   First Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
,
Nora Viniou
3   First Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
,
John Barbetseas
1   Department of Cardiology, Laikon General Hospital, Athens, Greece
› Author Affiliations
Further Information

Publication History

received: 28 July 2016

accepted in revised form: 01 February 2017

Publication Date:
28 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Atrial fibrillation (AF) is a major cause of stroke. The restoration of sinus rhythm through cardioversion, either chemical or electrical is a common practice. Interestingly, there is an incremental increase from the baseline risk for embolisation in the immediate post-cardioversion period, with most events occurring within 10 days from cardioversion. Especially patients with recent onset AF show the lowest rates of antithrombotic therapy, while having a high stroke risk. Despite the increased risk for embolisation, anticoagulation in patients undergoing cardioversion of atrial fibrillation is often inadequate. Moreover, since the implementation of non-vitamin K antagonists oral anticoagulants (DOACs) there are several therapeutic approaches for pericardioversion anticoagulant therapy and not all suits to all patients. In addition, the extensive use of transesophageal echocardiography provides an alternative strategy, especially useful for patients of high haemorrhagic risk. In this review article, we aim to provide an update on the anticoagulation strategies for patients undergoing cardioversion of non-valvular atrial fibrillation in the advent of the use of DOACs.

Zusammenfassung

Vorhofflimmern (VHF) ist eine der Hauptursachen für Schlaganfall. Die Wiederherstellung des Sinusrhythmus durch Kardioversion, entweder chemisch oder elektrisch, ist gängige Praxis. Interessanterweise steigt das Base - line-Embolierisiko unmittelbar nach Kardioversion schrittweise an, wobei die meisten Ereignisse innerhalb von 10 Tagen danach auftreten. V. a. Patienten mit neu aufgetretenem VHF haben die niedrigsten Raten an anti thrombotischer Therapie bei gleichzeitig hohem Schlaganfallrisiko. Ungeachtet des erhöhten Embolierisikos ist die Antikoagulation bei Patienten, die wegen VHF kardiovertiert werden, häufig unzureichend. Zudem gibt es seit der Einführung der nicht-Vitamin-K-antagonistischen direkten oralen Antikoagulantien (DOAK) mehrere therapeutische Ansätze für eine gerinnungshemmende Behandlung vor und nach der Kardioversion, aber nicht jeder Ansatz ist für alle Patienten geeignet. Die transösophagealen Echokardiographie ist eine alternative Strategie, v. a.für Patienten mit hohem Blutungsrisiko. In dieser Übersicht beschreiben wir den aktuellen Stand des Wissens zu antikoagulatorischen Strategien für Patienten, die wegen eines nicht valvulären VHF kardiovertiert werden.

Keywords

atrial fibrillation - cardioversion - anticoagulant therapy - transoesophageal echocardiography

Schlüsselwörter

Vorhofflimmern - Kardioversion - antikoagulative Therapie - transösophageale Echokardiographie
 

  • References

  • 1 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
    CrossrefPubMedGoogle Scholar
  • 2 Chugh SS, Blackshear JL, Shen WK. et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378.
    CrossrefPubMedGoogle Scholar
  • 3 Wang TJ, Larson MG, Levy D. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-2925.
    PubMedGoogle Scholar
  • 4 Kilander L, Andren B, Nyman H. et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998; 29: 1816-1820.
    CrossrefPubMedGoogle Scholar
  • 5 Benjamin EJ, Wolf PA, D’Agostino RB. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952.
    CrossrefPubMedGoogle Scholar
  • 6 Cappato R, Ezekowitz MD, Klein AL. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35: 3346-3355.
    CrossrefPubMedGoogle Scholar
  • 7 Flaker G, Lopes RD, Al-Khatib SM. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082-1087.
    CrossrefPubMedGoogle Scholar
  • 8 Nagarakanti R, Ezekowitz MD, Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
    CrossrefPubMedGoogle Scholar
  • 9 Arnold AZ, Mick MJ, Mazurek RP. et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855.
    CrossrefPubMedGoogle Scholar
  • 10 Garcia-Fernandez A, Marin F, Roldan V. et al. Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. Circ J 2016; 80: 605-612.
    CrossrefPubMedGoogle Scholar
  • 11 Hansen ML, Jepsen RM, Olesen JB. et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015; 17: 18-23.
    CrossrefPubMedGoogle Scholar
  • 12 Pisters R, Nieuwlaat R, Prins MH. et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 2012; 14: 666-674.
    CrossrefPubMedGoogle Scholar
  • 13 Lip GY, Gitt AK, Le Heuzey JY. et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol 2014; 113: 480-484.
    CrossrefPubMedGoogle Scholar
  • 14 Piccini JP, Stevens SR, Lokhnygina Y. et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006.
    CrossrefPubMedGoogle Scholar
  • 15 Grimm RA, Stewart WJ, Maloney JD. et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359-1366.
    CrossrefPubMedGoogle Scholar
  • 16 Akoum N, Fernandez G, Wilson B. et al. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2013; 24: 1104-1109.
    PubMedGoogle Scholar
  • 17 Habibi M, Lima JA, Khurram IM. et al. Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study. Circ Cardiovasc Imaging 2015; 08: e002769.
    CrossrefPubMedGoogle Scholar
  • 18 Daccarett M, Badger TJ, Akoum N. et al. Association of left atrial fibrosis detected by delayedenhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57: 831-838.
    CrossrefPubMedGoogle Scholar
  • 19 Lip GY, Lip PL, Zarifis J. et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-431.
    CrossrefPubMedGoogle Scholar
  • 20 Petersen P, Kastrup J, Vilhelmsen R, Schutten HJ. Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur Heart J 1988; 09: 639-641.
    CrossrefPubMedGoogle Scholar
  • 21 Jacob K, Talwar S, Copplestone A, Gilbert TJ, Haywood GA. Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin. Int J Cardiol 2004; 95: 83-88.
    CrossrefPubMedGoogle Scholar
  • 22 Vanassche T, Lauw MN, Eikelboom JW. et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36: 281-287a.
    CrossrefPubMedGoogle Scholar
  • 23 Grimm RA, Stewart WJ, Black IW. et al. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation?. J Am Coll Cardiol 1994; 23: 533-541.
    CrossrefPubMedGoogle Scholar
  • 24 Black IW, Fatkin D, Sagar KB. et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994; 89: 2509-2513.
    CrossrefPubMedGoogle Scholar
  • 25 Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92: 160-163.
    CrossrefPubMedGoogle Scholar
  • 26 Lupercio F, Carlos JRuiz, Briceno DF. et al. Left atrial appendage morphology assessment for risk stratification of embolic stroke in patients with atrial fibrillation: A meta-analysis. Heart Rhythm 2016; 13: 1402-1409.
    CrossrefPubMedGoogle Scholar
  • 27 Goette A, Merino JL, Ezekowitz MD. et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016; 388: 1995-2003.
    CrossrefPubMedGoogle Scholar
  • 28 Klein AL, Grimm RA, Murray RD. et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420.
    CrossrefPubMedGoogle Scholar
  • 29 Stellbrink C, Nixdorff U, Hofmann T. et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.
    CrossrefPubMedGoogle Scholar
  • 30 Klein AL, Jasper SE, Katz WE. et al. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomised multicentre study. Eur Heart J 2006; 27: 2858-2865.
    CrossrefPubMedGoogle Scholar
  • 31 Airaksinen KE, Gronberg T, Nuotio I. et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013; 62: 1187-1192.
    CrossrefPubMedGoogle Scholar
  • 32 Coleman CM, Khalaf S, Mould S. et al. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol 2015; 38: 731-737.
    CrossrefPubMedGoogle Scholar
  • 33 Kochhauser S, Khaykin Y, Beardsall J. et al. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. Can J Cardiol 2014; 30: 1541-1546.
    CrossrefPubMedGoogle Scholar
  • 34 Yadlapati A, Groh C, Passman R. Safety of shortterm use of dabigatran or rivaroxaban for directcurrent cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014; 113: 1362-1363.
    CrossrefPubMedGoogle Scholar
  • 35 Pallisgaard JL, Lindhardt TB, Hansen ML. et al. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. PLoS One 2015; 10: e0141377.
    CrossrefPubMedGoogle Scholar
  • 36 Briasoulis A, Kottam A, Khan M, Afonso L. Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation. J Thromb Thrombolysis 2015; 40: 139-143.
    CrossrefPubMedGoogle Scholar
  • 37 Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol 2015; 104: 582-590.
    CrossrefPubMedGoogle Scholar
  • 38 Sen P, Kundu A, Sardar P. et al. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis. Am J Cardiovasc Drugs 2016; 16: 33-41.
    CrossrefPubMedGoogle Scholar
  • 39 Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333: 5-10.
    CrossrefPubMedGoogle Scholar
  • 40 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
    CrossrefPubMedGoogle Scholar
  • 41 Plitt A, Ezekowitz MD, De Caterina R. et al. Cardioversion of Atrial Fibrillation in ENGAGE AFTIMI 48. Clin Cardiol 2016; 39: 345-346.
    CrossrefPubMedGoogle Scholar
  • 42 Reynolds MR. Cardioversion with novel oral anticoagulants: reconfirming a 50-year-old standard. J Am Coll Cardiol 2014; 63: 1088-1089.
    CrossrefPubMedGoogle Scholar
  • 43 McCready JW, Nunn L, Lambiase PD. et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory?. Europace 2010; 12: 927-932.
    CrossrefPubMedGoogle Scholar
  • 44 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962.
    CrossrefPubMedGoogle Scholar
  • 45 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: 2071-2104.
    CrossrefPubMedGoogle Scholar
  • 46 Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-755.
    CrossrefPubMedGoogle Scholar
  • 47 Manning WJ, Silverman DI, Keighley CS. et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25: 1354-1361.
    CrossrefPubMedGoogle Scholar
  • 48 Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691-704.
    CrossrefPubMedGoogle Scholar
  • 49 Gronberg T, Hartikainen JE, Nuotio I. et al. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). Am J Cardiol 2016; 117: 1294-1298.
    CrossrefPubMedGoogle Scholar
  • 50 Nuotio I, Hartikainen JE, Gronberg T. et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 2014; 312: 647-649.
    CrossrefPubMedGoogle Scholar
  • 51 Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-459.
    CrossrefPubMedGoogle Scholar
  • 52 Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129: 1204-1215.
    CrossrefPubMedGoogle Scholar
  • 53 Ezekowitz MD, Pollack CV, Sanders P. et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. Am Heart J 2016; 179: 59-68.
    CrossrefPubMedGoogle Scholar
  • 54 De Caterina R, Husted S, Wallentin L. et al. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 769-786.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Frost C, Wang J, Nepal S. et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
    CrossrefPubMedGoogle Scholar
  • 56 Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41: 1633-1652.
    CrossrefPubMedGoogle Scholar
  • 57 Hirsh J, Warkentin TE, Shaughnessy SG. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
    CrossrefPubMedGoogle Scholar
  • 58 Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177: 369-371.
    CrossrefPubMedGoogle Scholar
  • 59 Ogata K, Mendell-Harary J, Tachibana M. et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
    CrossrefPubMedGoogle Scholar
  • 60 O’Reilly RA, Aggeler PM, Hoag MS. et al. Hereditary Transmission of Exceptional Resistance to Coumarin Anticoagulant Drugs. The First Reported Kindred. N Engl J Med 1964; 271: 809-815.
    CrossrefPubMedGoogle Scholar
  • 61 Stangier J, Rathgen K, Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
    CrossrefPubMedGoogle Scholar
  • 62 Wang L, Zhang D, Raghavan N. et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448-458.
    CrossrefPubMedGoogle Scholar
  • 63 Weinz C, Schwarz T, Kubitza D. et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-1064.
    CrossrefPubMedGoogle Scholar